Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome.

Fischer MJ, Ho PM, McDermott K, Lowy E, Parikh CR.

BMC Nephrol. 2013 May 20;14:107. doi: 10.1186/1471-2369-14-107.

2.

Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.

Lin TH, Lai WT, Hsin HT, Li AH, Wang CL, Kuo CT, Hwang JJ, Chiang FT, Chang SC; ACS Full Spectrum Registry Investigators..

PLoS One. 2013 Aug 28;8(8):e71917. doi: 10.1371/journal.pone.0071917. eCollection 2013.

3.

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS.

JAMA. 2009 Mar 4;301(9):937-44. doi: 10.1001/jama.2009.261.

PMID:
19258584
4.

Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.

Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S.

Heart. 2015 Oct;101(19):1569-76. doi: 10.1136/heartjnl-2014-307168. Epub 2015 Jul 24.

5.

One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.

Ortolani P, Marino M, Marzocchi A, De Palma R, Branzi A.

J Cardiovasc Med (Hagerstown). 2012 Dec;13(12):783-9. doi: 10.2459/JCM.0b013e3283416b6b.

PMID:
21252697
6.

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.

Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS.

JAMA. 2008 Feb 6;299(5):532-9. doi: 10.1001/jama.299.5.532. Erratum in: JAMA. 2008 May 28;299(20):2390.

PMID:
18252883
7.

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.

Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A.

J Am Coll Cardiol. 2014 Mar 25;63(11):1061-70. doi: 10.1016/j.jacc.2013.12.023. Epub 2014 Jan 30.

8.

GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry.

Bae EH, Lim SY, Cho KH, Choi JS, Kim CS, Park JW, Ma SK, Jeong MH, Kim SW.

Am J Kidney Dis. 2012 Jun;59(6):795-802. doi: 10.1053/j.ajkd.2012.01.016. Epub 2012 Mar 23.

PMID:
22445708
9.

Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.

Wiederkehr D, Berenson K, Casciano R, Stern L, Makenbaeva D, Mozaffari E, Lamerato L, Corbelli J.

Curr Med Res Opin. 2009 Sep;25(9):2317-25. doi: 10.1185/03007990903156061.

PMID:
19635042
10.

Impact of renal dysfunction on long-term outcomes of elderly patients with acute coronary syndrome: a longitudinal, prospective observational study.

Liu Y, Gao L, Xue Q, Yan M, Chen P, Wang Y, Li Y.

BMC Nephrol. 2014 May 9;15:78. doi: 10.1186/1471-2369-15-78.

11.

Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.

Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, Caillard S, Campia U, Moulin B, Gachet C, Ohlmann P.

J Am Coll Cardiol. 2011 Jan 25;57(4):399-408. doi: 10.1016/j.jacc.2010.09.032.

12.

Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.

Akerblom Å, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA, Steg PG, Storey RF, Åsenblad N, James SK.

Clin Chem. 2012 Jan;58(1):190-9. doi: 10.1373/clinchem.2011.171520. Epub 2011 Nov 29.

13.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
14.

Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.

Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW.

Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1043-9. doi: 10.1002/pds.2202. Epub 2011 Aug 8.

PMID:
21823195
15.

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.

Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK.

Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. Epub 2014 May 15.

PMID:
24830710
16.

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.

Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC.

J Am Coll Cardiol. 2008 Nov 18;52(21):1693-701. doi: 10.1016/j.jacc.2008.08.031.

17.

Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.

Wiederkehr D, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Corbelli J.

Curr Med Res Opin. 2009 Sep;25(9):2327-34. doi: 10.1185/03007990903156087.

PMID:
19635046
18.

Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.

Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC.

Catheter Cardiovasc Interv. 2010 Oct 1;76(4):513-24. doi: 10.1002/ccd.22546.

PMID:
20882655
19.

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.

James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L.

Circulation. 2010 Sep 14;122(11):1056-67. doi: 10.1161/CIRCULATIONAHA.109.933796. Epub 2010 Aug 30.

20.

Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes.

Tseng CL, Lafrance JP, Lu SE, Soroka O, Miller DR, Maney M, Pogach LM.

BMC Nephrol. 2015 Mar 25;16:34. doi: 10.1186/s12882-015-0025-5.

Supplemental Content

Support Center